Was this a deal to delay generic competition? BD
A botched 2006 deal to keep generic Plavix off the market already led Bristol-Myers Squibb to oust its CEO, plead guilty to a federal charge and pay a $1 million fine. Today, in a distant aftershock, a former Bristol SVP was indicted for allegedly misleading the government about the deal. According to the indictment (Andrew Bodnar told regulators that Bristol hadn’t promised not to compete against Apotex when the company brought out a generic version of the blood thinner. When Bristol agreed to pay the $1 million fine, the company said Bodnar, a senior vice president at the time, had cut such a deal and lied about it to the Federal Trade Commission, the WSJ reported last year. The indictment repeats those allegations.
Health Blog : Former Bristol-Myers Exec Indicted, Accused of Lying to Feds
0 comments :
Post a Comment